# SEC Form 4

 $\Box$ 

# FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to	)
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

# OMB APPROVAL

OMB Number:	3235-0287
Estimated average burd	len
hours per response:	0.5

1. Name and Addres Mahatme San	ss of Reporting Person Idesh	۱*	2. Issuer Name <b>and</b> Ticker or Trading Symbol Sarepta Therapeutics, Inc. [SRPT]		tionship of Reporting Perso all applicable) Director	10% Owner					
(Last) 215 FIRST STR	(First) EET, SUITE 415	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 01/30/2019	x	Officer (give title below) EVP, CFO & C	Other (specify below) CBO					
(Street) CAMBRIDGE (City)	MA (State)	02142 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	idual or Joint/Group Filing ( Form filed by One Report Form filed by More than ( Person	ting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned											
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	01/30/2019		<b>M</b> <sup>(1)</sup>		5,469	A	\$13.71	14,118	D		
Common Stock	01/30/2019		<b>M</b> <sup>(1)</sup>		1,128	A	\$13.71	15,246	D		
Common Stock	01/30/2019		<b>M</b> <sup>(1)</sup>		17,860	A	\$13.9	33,106	D		
Common Stock	01/30/2019		<b>M</b> <sup>(1)</sup>		19,345	A	\$23.85	52,451	D		
Common Stock	01/30/2019		S <sup>(1)</sup>		43,802	D	\$130	8,649	D		
Common Stock	01/31/2019		M <sup>(1)</sup>		21,198	A	\$23.85	29,847	D		
Common Stock	01/31/2019		S <sup>(1)</sup>		21,198	D	\$130.72	8,649	D		
Common Stock								12,012	I	By trust	

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 6. Date Exercisable and 7. Title and Amount 9. Number of 3. Transaction 3A. Deemed 5. Number 8. Price of 11. Nature 10. Conversion Date Execution Date, Transaction of Expiration Date (Month/Day/Year) of Securities Derivative Security derivative Ownership of Indirect Beneficial or Exercise Price of Derivative Security Underlying Derivative Security (Instr. 3 and 4) (Month/Day/Year) if any (Month/Day/Year) Code (Instr. 8) Derivative Securities Form: Direct (D) (Instr. 5) Securities Beneficially Ownership Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) Owned Following or Indirect (I) (Instr. 4) (Instr. 4) Reported Transaction(s) (Instr. 4) Amount or Number of Date Expiration

			Code	v	(A)	(D)	Exercisable	Date	Title	Shares				
Stock Option (right to buy)	\$13.71	01/30/2019	<b>M</b> <sup>(1)</sup>			5,469	02/28/2017	02/28/2026	Common Stock	5,469	\$0.00	7,404	D	
Stock Option (right to buy)	\$13.71	01/30/2019	<b>M</b> <sup>(1)</sup>			1,128	02/28/2017	02/28/2026	Common Stock	1,128	\$0.00	6,771	D	
Stock Option (right to buy)	\$13.9	01/30/2019	<b>M</b> <sup>(1)</sup>			17,860	02/27/2016	02/27/2025	Common Stock	17,860	\$0.00	0	D	
Stock Option (right to buy)	\$23.85	01/30/2019	M <sup>(1)</sup>			19,345	11/05/2013	11/05/2022	Common Stock	19,345	\$0.00	96,664	D	
Stock Option (right to buy)	\$23.85	01/31/2019	<b>M</b> <sup>(1)</sup>			21,198	11/05/2013	11/05/2022	Common Stock	21,198	\$0.00	75,466	D	

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 Plan. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.

**Remarks:** 

/s/ David Tyronne Howton, as attorney-in-fact for Sandesh Mahatme

02/01/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.